Tianjin Ringpu Bio Tech (300119) — Strategic Asset Allocation Index
Tianjin Ringpu Bio Tech (300119) has a Strategic Asset Allocation Index of 36.6% as of June 2023. Strategic assets (PP&E of CN¥1.66 Billion plus long-term investments of CN¥-) total CN¥1.66 Billion, measured against net assets of CN¥4.54 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Tianjin Ringpu Bio Tech Strategic Asset Allocation Index (2007–2021)
This chart shows how Tianjin Ringpu Bio Tech's Strategic Asset Allocation Index has evolved across 15 annual periods from 2007 to 2021. As of June 2023, the index stands at 36.6%, representing strategic assets of CN¥1.66 Billion against net assets of CN¥4.54 Billion CNY. Explore 300119 cash generation efficiency to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Tianjin Ringpu Bio Tech (2007–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Tianjin Ringpu Bio Tech from 2007 to 2021, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market cap of Tianjin Ringpu Bio Tech.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 30.1% | CN¥1.30 Billion | CN¥1.30 Billion | CN¥- | CN¥4.32 Billion | ▼ -10.7 pp |
| 2020 | 40.7% | CN¥1.11 Billion | CN¥1.11 Billion | CN¥- | CN¥2.74 Billion | ▼ -3.1 pp |
| 2019 | 43.8% | CN¥1.03 Billion | CN¥1.03 Billion | CN¥- | CN¥2.36 Billion | ▼ -8.5 pp |
| 2018 | 52.3% | CN¥1.18 Billion | CN¥953.87 Million | CN¥225.01 Million | CN¥2.25 Billion | ▼ -0.7 pp |
| 2017 | 53.0% | CN¥1.15 Billion | CN¥929.30 Million | CN¥224.69 Million | CN¥2.18 Billion | ▼ -0.1 pp |
| 2016 | 53.1% | CN¥1.12 Billion | CN¥935.56 Million | CN¥183.06 Million | CN¥2.11 Billion | ▼ -4.4 pp |
| 2015 | 57.6% | CN¥1.02 Billion | CN¥920.37 Million | CN¥98.10 Million | CN¥1.77 Billion | ▲ +11.1 pp |
| 2014 | 46.5% | CN¥802.93 Million | CN¥802.93 Million | CN¥- | CN¥1.73 Billion | ▼ -1.2 pp |
| 2013 | 47.7% | CN¥820.74 Million | CN¥820.74 Million | CN¥- | CN¥1.72 Billion | ▲ +12.5 pp |
| 2012 | 35.2% | CN¥558.48 Million | CN¥558.48 Million | CN¥- | CN¥1.59 Billion | ▲ +14.3 pp |
| 2011 | 20.9% | CN¥312.91 Million | CN¥312.91 Million | CN¥- | CN¥1.50 Billion | ▲ +6.2 pp |
| 2010 | 14.7% | CN¥209.91 Million | CN¥209.91 Million | CN¥- | CN¥1.43 Billion | ▼ -31.0 pp |
| 2009 | 45.7% | CN¥115.36 Million | CN¥115.36 Million | CN¥- | CN¥252.48 Million | ▲ +7.5 pp |
| 2008 | 38.2% | CN¥95.58 Million | CN¥95.58 Million | CN¥- | CN¥249.97 Million | ▼ -2.7 pp |
| 2007 | 40.9% | CN¥55.74 Million | CN¥55.74 Million | CN¥- | CN¥136.21 Million | — |